Differential effects of pharmacological modulators of cardiac myofibrillar ATPase activity in normal and myopathic (BIO 14.6) hamsters.
The effects of four Ca2+ binding protein modulators (bepridil, perhexiline, calmidazolium and trifluoperazine) on cardiac myofibrillar ATPase activity in Triton-purified myofibrils prepared from normal dogs, normal hamsters and age/sex (male, 16-20 weeks)-matched myopathic hamsters (BIO 14.6) have been quantitated. When compared with normal hamsters, myopathic hamster myofibrils have a markedly depressed maximum MgATPase activity (178 +/- 2 vs. 119 +/- 3 nmol/mg per min, respectively) and a slightly increased requirement of Ca2+ for half-maximal activation (ED50; 0.66 vs. 0.75 microM free Ca2+, respectively). Calmidazolium, trifluoperazine and bepridil lower the ED50 for Ca2+ in myopathic myofibrils. Moreover, bepridil and trifluoperazine increase maximum myofibrillar MgATPase activity in myopathic hamster myofibrils. In contrast, calmidazolium depresses maximum and stimulates basal MgATPase activities in myopathic and normal hamster myofibrils. Qualitatively, different effects are apparent when these agents are examined in canine myofibrils. Thus, the pharmacological effects of Ca2+ binding protein modulators on cardiac myofibrillar ATPase activity are dependent upon species and/or pathological state. It is possible to directly enhance a pathological consequence of cardiac myopathy, depression in maximum myofibrillar MgATPase activity, with pharmacological agents.
Silver
P J
PJ
Department of Pharmacology, Sterling-Winthrop Research Institute, Rensselaer, NY 12144.
Monteforte
P B
PB
D000251:Adenosine Triphosphatases / Q000037:antagonists & inhibitors*; D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000494:pharmacology; D015764:Bepridil; D002118:Calcium / Q000494:pharmacology; D002121:Calcium Channel Blockers / Q000494:pharmacology*; D006224:Cricetinae; D004195:Disease Models, Animal; D004591:Electrophoresis, Polyacrylamide Gel; D006333:Heart Failure / Q000201:enzymology*; D007093:Imidazoles / Q000494:pharmacology; D008297:Male; D009206:Myocardium / Q000201:enzymology*; D009210:Myofibrils / Q000201:enzymology*; D010480:Perhexiline / Q000494:pharmacology; D011759:Pyrrolidines / Q000494:pharmacology; D014268:Trifluoperazine / Q000494:pharmacology
D000889:Anti-Arrhythmia Agents; D002121:Calcium Channel Blockers; D007093:Imidazoles; D011759:Pyrrolidines; D014268:Trifluoperazine; C031938:calmidazolium; D015764:Bepridil; D000251:Adenosine Triphosphatases; D010480:Perhexiline; D002118:Calcium